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Abstract
Background: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in
a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic
acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy.
We evaluated the AHP disease burden in patients aged ≥ 12 years in a post hoc analysis of the Phase 3, randomized,
double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic
that targets the enzyme ALAS1 to decrease ALA and PBG production. We analyzed baseline AHP severity via chronic
symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality
of life (QOL) and evaluated givosiran (2.5 mg/kg monthly) in patients with and without prior hemin prophylaxis on
number and severity of attacks and pain scores during and between attacks.
Results: Participants (placebo, n = 46; givosiran, n = 48) included patients with low and high annualized attack rates
(AARs; range 0–46). At baseline, patients reported chronic symptoms (52%), including nausea, fatigue, and pain;
comorbidities, including neuropathy (38%) and psychiatric disorders (47%); concomitant medications, including
chronic opioids (29%); hemin-associated complications (eg, iron overload); and poor QOL (low SF-12 and EuroQol
visual analog scale scores). A linear relationship between time since diagnosis and AAR with placebo suggested wors‑
ening of disease over time without effective treatment. Givosiran reduced the number and severity of attacks, days
with worst pain scores above baseline, and opioid use versus placebo.
Conclusions: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may
partly be alleviated with givosiran.
Keywords: Acute hepatic porphyria, Givosiran, Disease burden, Porphyria attack, Chronic symptoms, Quality of life
Background
Acute hepatic porphyria (AHP) is a family of rare genetic
diseases, each arising from a deficiency in an enzyme
involved in hepatic heme biosynthesis [1]. These enzyme
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defects cause depletion of free heme and increase the
demand for hepatic heme, resulting in up-regulation
of the ALAS1 enzyme and overproduction of the toxic
heme intermediates delta-aminolevulinic acid (ALA) and
porphobilinogen (PBG) [2]. Accumulation of ALA and
PBG is thought to cause injury primarily to the nervous
system, as well as to other organs, such as the liver and
kidneys [2–4]. Of the four subtypes of AHP, the most
common is acute intermittent porphyria (AIP) [1]. AHP
manifests predominantly in females between the ages of
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20 and 40 years [5, 6], and the overall symptomatic prevalence is 1 per 100,000 persons [7, 8]. While most symptomatic patients experience only a few attacks in their
lifetime, up to 8% have recurrent attacks (≥ 4 attacks per
year) [9].
AHP is a multisystem disease characterized by disabling acute neurovisceral attacks, most often including severe abdominal pain, vomiting, muscle weakness,
hypertension, and changes in mental status [2]. Chronic
manifestations occur between attacks and progress over
the disease course [2, 6, 10, 11]. In a multinational natural history study of 112 patients with AHP experiencing
recurrent attacks (EXPLORE), 77% of attacks required
treatment at a healthcare facility and/or administration of hemin [11]. Attacks not treated promptly or that
frequently recur may lead to progressive or irreversible
neuropathy and prolonged debilitation [2, 11]. Approximately 59% of patients with recurrent attacks will
develop chronic kidney disease [12]. Recurrent AHP also
has a long-term impact on mental functioning, affecting
activities of daily living [6, 10, 13]. Patients report diminished quality of life (QOL) and significant economic burden [11, 14].
Early treatment is important to prevent disease progression [5, 15]. There is a need for treatments that not
only reduce or eliminate acute attacks, but also improve
chronic manifestations of recurrent AHP. Prevention
strategies include identifying and avoiding triggers that
may precipitate acute attacks [16, 17]. However, some
triggers, such as stress, may not always be avoidable [17,
18]. Furthermore, many patients continue to experience
chronic symptoms between attacks [6, 10, 11]. Opioids
are used to manage abdominal, limb, and back pain [17],
but patients receiving opioids may develop somnolence,
addiction, tolerance, and hyperalgesia [19].
Intravenous (IV) hemin is the standard of care for
confirmed acute attacks [2, 20, 21]. Hemin is thought
to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [22–24].
Although hemin is not indicated for prophylaxis [22,
23], it is often used off-label for this purpose [11]. Some
patients have reported recurrent attacks despite weekly
prophylactic hemin administration [25]. Side effects and
complications associated with hemin use include headache, infusion-site reactions, and phlebitis, and chronic
complications, such as tachyphylaxis, coagulation
abnormalities, venous damage, and secondary iron overload [25, 26]. Chronic hemin use is also associated with
liver inflammation and fibrosis [25]. Patients may also
have complications from the indwelling central venous
catheter required to administer hemin on a regular basis,
including catheter occlusion, bacteremia, and thromboembolism [25].
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Liver transplantation is considered a last resort for
patients with severe recurrent attacks that do not
respond to hemin [5, 26, 27]. It is not suitable for most
patients, and there is a shortage of donors [11, 28]. It also
has a significant risk of morbidity and mortality that is
comparable to that faced by patients who received transplants for other metabolic diseases [11, 25, 27].
Thus, treatment options for recurrent AHP were limited before the approval of givosiran, a subcutaneously
administered RNA interference (RNAi) therapeutic that
specifically targets ALAS1 messenger RNA in the liver to
reduce production of ALA and PBG [29, 30]. Givosiran
is indicated for the treatment of AHP in adults (United
States, Brazil, Canada) and adolescents aged 12 years and
older (European Economic Area, United Kingdom, Switzerland, Japan) [31–34] based on the results of the phase
3 ENVISION trial [35]. In ENVISION (NCT03338816),
givosiran treatment was associated with a 74% reduction in the mean annualized rate of composite porphyria
attacks (AAR) in patients with AIP compared with placebo (3.2 vs. 12.5, respectively; P < 0.001) [35]. Givosiran
treatment also reduced urinary ALA and PBG levels
and hemin use and was associated with improvement
in pain and QOL assessment scores. Continued treatment through month 24 led to sustained reductions in
ALA and PBG levels, porphyria attacks, and hemin use,
and to further improvements in QOL and other patientreported outcomes [36]. The proportion of patients with
no attacks increased over time, with 83% of patients
who received continuous givosiran treatment remaining
attack-free during the 3 months prior to Month 24 [36].
The safety profile of givosiran was acceptable, and most
adverse events (AEs) were mild or moderate in severity
[35, 36].
This post hoc analysis used data from the ENVISION
trial to evaluate the disease burden associated with AHP,
including patients with a low rate of acute attacks (< 7
attacks or < 12 attacks in the previous 12 months among
patients who were and were not receiving hemin at baseline, respectively). The efficacy of givosiran in patients
with and without prior hemin use was also assessed,
including patient-reported pain scores during and
between attacks.

Methods
ENVISION trial design

The study population was defined as patients
aged ≥ 12 years with a diagnosis of AHP, an elevated
level of urinary ALA or PBG (≥ 4 times the upper limit
of normal), and either a confirmed pathogenic mutation
associated with AHP or biochemical and clinical criteria consistent with a diagnosis of AHP [35]. Patients
were also required to have experienced ≥ 2 porphyria

Wang et al. Orphanet Journal of Rare Diseases

(2022) 17:327

Page 3 of 12

attacks requiring hospitalization, urgent health care,
or IV administration of hemin at home in the previous 6 months [35]. Details regarding study subjects and
methodology of the ENVISION study have been previously reported [35].
Thirty-six study sites in 18 countries participated in the
study [35]. Patients were randomized to receive monthly
subcutaneous givosiran 2.5 mg/kg or matching placebo
for 6 months [35]. Randomization was stratified according to AHP subtype, previous use or nonuse of hemin
prophylaxis, and a low or high AAR in the previous
12 months (< 7 attacks [low] vs. ≥ 7 attacks [high] among
patients who were receiving hemin prophylaxis at baseline and < 12 attacks [low] vs. ≥ 12 attacks [high] among
those who were not receiving hemin prophylaxis) [35].
Outcome measures

The primary endpoint was AAR (requiring hospitalization, urgent health care, or IV administration of hemin
at home) among patients with AIP [35]. Secondary endpoints included AAR among all patients with AHP; rate
of administered hemin doses; daily worst scores for pain,
fatigue, and nausea; and QOL assessments in patients
with AIP. Exploratory endpoints included analgesic usage
(opioid and non-opioid).
Daily worst pain and daily worst fatigue scores were
measured using the Brief Pain Inventory-Short Form
(BPI-SF) and Brief Fatigue Inventory-Short Form (BFISF) numerical rating scales (NRS), respectively. An NRS
was also used for daily worst nausea score. All NRS
ranged from 0 to 10, with higher scores indicating more
severe symptoms; scores were captured using a daily eDiary from screening through Month 12.
QOL assessments included the 12-Item Short-Form
Health Survey, version 2 (SF-12), and the EuroQol-5
Dimension-5 Level Questionnaire (EQ-5D-5L) and were
collected throughout the study. The SF-12 generates 8
domains of functional health and well-being, including
bodily pain, in addition to physical component summary

(PCS) and mental component summary (MCS) scores.
Low scores on the PCS indicate limitations in physical
functioning, high bodily pain, and poor general health.
The EQ-5D-5L assesses 5 dimensions, as well as patient’s
global impression of their overall health on a visual
analog scale (EQ VAS), which ranges from 0 (worst possible health) to 100 (best possible health).
Post hoc analyses

A review of ENVISION trial data was undertaken to fully
examine the severity of AHP disease burden at baseline,
including the prevalence of chronic symptoms, comorbidities, concomitant medications, prophylactic hemin
use and associated complications, and patient QOL. Additional measurements included lost days of work due to
AHP and hours of caregiver support required. The association between time since diagnosis and AAR was also
examined. Furthermore, post hoc analyses were undertaken to examine the effects of givosiran treatment on
the number and severity of attacks in patients with AHP
according to prior hemin prophylaxis, and on daily worst
pain scores and analgesic use during attack-free periods.
These analyses were not protocol-defined, and therefore
no formal statistical comparisons were undertaken.

Results
A total of 94 patients with AHP were enrolled in the
ENVISION trial, of whom 46 were assigned to receive
placebo and 48 to receive givosiran [35]. The median
(range) age was 37.5 (19‒65) years, and the mean (SD)
years since diagnosis was 9.7 (10.0) [35]. The median
(range) AAR in the 6 months prior to study randomization was 8.0 (0–46) [35].
At baseline, 52% of patients were experiencing chronic
symptoms of porphyria, defined as symptoms between
attacks daily or on most days [35]. Chronic symptoms
included nausea, fatigue, and pain (Table 1). Opioid analgesics were used daily or on most days between attacks in
29% of patients [35]. Mean daily worst fatigue score was

Table 1 Chronic symptoms in ENVISION trial participants at baseline
Characteristic

Placebo (n = 46)

Givosiran (n = 48)

Total (N = 94)

Prior chronic symptoms, n (%)

26 (57)

23 (48)

Prior chronic opioid use, n (%)

13 (28)

14 (29)

27 (29)

Nausea symptoms (medical history), n (%)

10 (22)

7 (15)

17 (18)

Fatigue (medical history), n (%)
Daily worst nausea score, weekly mean (SD)

49 (52)

4 (9)

1 (2)

5 (5)

1.9 (1.8)

1.6 (1.7)

1.7 (1.8)

Daily worst fatigue score, weekly mean (SD)

4.7 (2.3)

4.1 (2.6)

4.4 (2.5)

Daily worst pain score, weekly mean (SD)

3.7 (2.2)

3.0 (2.3)

3.3 (2.3)

34.4 (9.0)

37.6 (9.9)

36.0 (9.6)

Bodily pain domain score (SF-12), mean (SD)
SF-12 12-Item Short-Form Health Survey, version 2
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above 4, on a numerical rating scale of 0–10, in both treatment groups.
Patients had a poor QOL at baseline, as measured using
the SF-12 PCS, SF-12 MCS, and EQ VAS (Table 2). While
the study population was of working age (19–65 years),
only 44% of patients were employed. Those who were
employed missed a mean of 6 days and 3 days within the
4 weeks prior to their baseline visit in the placebo and
givosiran group, respectively.
A high proportion of patients had comorbidities,
including peripheral neuropathy, hypertension, liver and
kidney disease, and psychiatric disorders (Fig. 1). Sensory
neuropathy was present in 19% of patients, motor neuropathy in 22% of patients, and autonomic neuropathy in
3% of patients. Overall rates of depression, anxiety, and
insomnia were 27%, 23%, and 18%, respectively. A total

of 29% of patients reporting being moderately, severely,
or extremely anxious or depressed. Mean score for the
SF-12 MCS was lower (40.9) than the population norm
(50.0) [37], suggesting that AHP has a negative impact on
mental health. Many patients were also taking concomitant medications that coincide with common comorbidities, including antidepressants, antihypertensives,
antiemetics, and opioids (Table 3).
A high proportion of patients had received prior hemin
prophylaxis (40%) [11], with many experiencing heminrelated complications, as well as ongoing damage caused
by AHP (Fig. 2). Complications related to central venous
access included thrombosis (8%), infection (18%), and
catheter occlusion/malfunction (24%). Disease burden
was also high in patients who had not received prior
hemin prophylaxis (60%) (Table 4).

Table 2 Quality of life in ENVISION trial participants at baseline
Assessment, Mean (SD)

Placebo (n = 46)

Givosiran (n = 48)

SF-12 PCS

38.1 (9.8)

39.5 (9.8)

SF-12 MCS

41.8 (10.3)

39.9 (8.3)

EQ VAS

64.3 (19.6)

62.6 (22.6)

Employed in past 4 weeks, n

21

20

6.1 (6.5)

3.3 (3.5)

11.3 (28.1)

12.5 (32.3)

Days of work missed in past 4 weeks
Hours of caregiver support in past week

EQ VAS EuroQol visual analog scale, MCS mental component summary, PCS physical component summary, SF-12 12-Item Short-Form Health Survey, version 2

60
54
50

47
42

Patients, %

40

39

38
35

35

30
24

27 26

39

37

34
29

28

28 27 28

39

25
21

20

10

0

Neuropathy

Hypertension

Liver
disease

Placebo (n=46)

Fig. 1 Comorbidities in ENVISION trial participants at baseline

Elevated
transaminases
Givosiran (n=48)

Kidney
Psychiatric
eGFR
failure and <60 mL/min/1.73 m2 disorders
impairment
Total (N=94)
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Table 3 Concomitant antidepressants, antihypertensives, antiemetics, and analgesics at baseline
Placebo (n = 46)

Givosiran (n = 48)

Total (N = 94)
20 (21)

Antidepressants
Benzodiazepine derivatives

10 (22)

10 (21)

Benzodiazepine-related drugs

3 (7)

4 (8)

7 (7)

Other anti-depressants

4 (9)

9 (19)

13 (14)

SSRIs

2 (4)

4 (8)

6 (6)

Antihypertensives
ACE inhibitors

2 (4)

1 (2)

3 (3)

Angiotensin II receptor antagonists

3 (7)

2 (4)

5 (5)

Beta blocking agents, non-selective

1 (2)

3 (6)

4 (4)

Beta blocking agents, selective

5 (11)

7 (15)

12 (13)

12 (26)

12 (25)

24 (26)

27 (59)

23 (48)

50 (53)

Antiemetics
5HT3 antagonists
Pain medications
Natural opium alkaloids
Opioid anesthetics (fentanyl)

2 (4)

0

Opioid/non-opioid combinations

2 (4)

5 (10)

2 (2)
7 (7)

Opium alkaloid derivatives

2 (4)

0

2 (2)

Other opioids

8 (17)

6 (13)

14 (15)

Other analgesics and antipyretics 10 (22)

13 (27)

23 (25)

SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, 5HT3 5-hydroxytryptamine

100
90

89
85

80

Patients, %

70
60

64

61

57

50

50

44

40

35
29

30

29
21

20

14

10
0

Current or prior catheter use
Placebo (prior hemin)
(n=18)

Complications related to
central venous access

Givosiran (prior hemin)
(n=20)

Placebo (no prior hemin)
(n=28)

Diagnosed iron overload
Givosiran (no prior hemin)
(n=28)

Fig. 2 Complications and comorbidities in ENVISION trial participants according to hemin prophylaxis at baseline
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Table 4 Disease severity in ENVISION trial participants according to hemin prophylaxis at baseline
No prior hemin prophylaxis

Prior hemin prophylaxis

Placebo (n = 28)

Placebo (n = 18)

Givosiran (n = 28)

Givosiran (n = 20)

Historical AAR, median (range)

6.0 (0–46)

8.0 (4–34)

9.0 (4–38)

9.0 (4–32)

Chronic symptoms, n (%)

17 (61)

16 (57)

9 (50)

7 (35)

Chronic opioid use, n (%)

7 (25)

6 (21)

6 (33)

8 (40)

EQ VAS, mean (SD)

63.9 (20.7)

58.4 (23.0)

64.8 (18.4)

68.4 (21.3)

SF-12 PCS, mean (SD)

36.5 (10.5)a

39.3 (11.2)

40.5 (8.4)

39.7 (7.8)

AARannualized attack rate, EQ VAS EuroQol visual analog scale, PCS physical component summary, SF-12 12-Item Short-Form Health Survey, version 2
a

Data missing for 1 patient

There was a linear relationship between longer time
since diagnosis of AHP and higher AAR in the placebo
group during the 6-month double-blind treatment period
of the ENVISION trial (Fig. 3; r = 0.403; P < 0.01). This suggests that AHP disease worsening likely occurs over time.
The number of attacks, and attack severity, were both
reduced in patients with AHP receiving givosiran compared with those receiving placebo, regardless of prior
hemin use (Fig. 4). The total number of attacks among
those with no prior hemin prophylaxis was 42 in the
givosiran group versus 111 in the placebo group. Corresponding numbers among those who did have prior
hemin prophylaxis were 48 and 186, respectively. The
proportion of patients with ≥ 1 attack, the proportion of
attacks with a median pain score ≥ 7, and the proportion
of patients with ≥ 1 attack with a median pain score ≥ 7
were all lower in the givosiran group compared with the
placebo group (Fig. 5).

AHP patients who received givosiran had reduced
pain and analgesic use both during and between attacks
compared with those who received placebo. Those in
the givosiran group also had fewer days with daily worst
pain scores above baseline (Fig. 6). Furthermore, they
reported nearly 50% fewer days with severe pain during attack-free periods compared with placebo recipients (proportion of days with a pain score ≥ 7; 7% vs.
12%). Opioid analgesics were used by 73% of patients in
the givosiran group and 85% of patients in the placebo
group during attacks [38]. Corresponding percentages
during attack-free periods were 56% and 70%, respectively [38]. The proportion of days with opioid use
was reduced in patients with AHP receiving givosiran
compared with placebo, regardless of prior hemin use
(Fig. 7). Givosiran treatment was also associated with
improved QOL, measured by higher SF-12 PCS scores
(Fig. 8).

20
18

Mean Historical AAR

16
14

13.2

12.4

12
10

9.0

8.9

8
6
4
2
0

≤3 years

>3 years

≤5 years

>5 years

Time Since Diagnosis
Fig. 3 Association between years since diagnosis of AHP and mean historical annualized attack rate during ENVISION trial
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Continuous givosiran
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5

2.1

0

1.8

0.0

Prior hemin
prophylaxis

No prior hemin
prophylaxis

1.3

0.0

Prior hemin
prophylaxis

0.0

No prior hemin
prophylaxis

Prior Hemin Prophylaxis
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OLE Period

DB Period

100

Placebo crossover
Continuous givosiran

80
60
40
20
0

Baseline >0–3

No. of patients
18
Placebo/Givosiran
Givosiran/Givosiran 20

>3–6
18
20

18
20

>6–9
18
20

>9–12
17
20

>12–15 >15–18 >18–21
17
19

Month Interval
17
19

16
19

>21–24 >24–27 >27–30
16
19

15
19

8
11

Attack-Free Patients
by 3-Month Interval, %

No Prior Hemin Prophylaxis
100

Placebo crossover
Continuous givosiran

80
60
40
20
0

Baseline >0–3

No. of patients
Placebo/Givosiran
Givosiran/Givosiran

28
28

45
40
35
30
25
20
15
10
5
0

>3–6

>6–9

28
28

28
28

C.
Median Annualized
Days of Hemin Use

OLE Period

DB Period

28
28

>9–12
28
27

>12–15 >15–18 >18–21

Month Interval
28
27

27
27

27
27

DB Period
(0–6 months)

39.1

>21–24 >24–27 >27–30
26
27

26
27

10
11

OLE Period
(6–24 months)
Placebo crossover
Continuous givosiran

8.6
3.1
Prior hemin
prophylaxis

0.0
No prior hemin
prophylaxis

1.8

0.0

Prior hemin
prophylaxis

0.0

0.0

No prior hemin
prophylaxis

Fig. 4 Attack frequency (A), proportion of attack-free patients by 3-month interval (B), and hemin use (C) with long-term givosiran treatment in
patients with or without prior hemin prophylaxis usea. aHemin prophylaxis was not allowed during the study; days of hemin use therefore refers
only to hemin used to treat attacks

Discussion
This study used data from the ENVISION trial to demonstrate the severe disease burden associated with recurrent AHP. At baseline, more than half of ENVISION trial

patients were experiencing chronic symptoms between
attacks, including nausea, fatigue, and pain, and more
than one quarter had been using opioids daily or on most
days [35]. We also found a positive correlation between

Wang et al. Orphanet Journal of Rare Diseases

100

(2022) 17:327

Page 8 of 12

94

90
80

77

75

Patients, %

70
60

55

55

50

52

46

40

36
31

30

26

24

19

20
10
0

Placebo (prior hemin)
(n=18)

Givosiran (prior hemin)
(n=20)

Placebo (no prior hemin)
(n=28)

Givosiran (no prior hemin)
(n=28)

Fig. 5 Proportions of patients with ≥ 1 attack at Month 6 in ENVISION trial according to hemin prophylaxis at baseline

60

55
Placebo

50

Givosiran

45
42

% of Days

40
33
30

34

28
24

20

19

16

18
11

10

0

25

12
7

Worse than
baseline

Fig. 6 Daily worst pain scores during attack-free periods in ENVISION trial

time since diagnosis and AHP disease severity, further
highlighting the need to treat patients early with effective therapy. These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent
AHP regardless of prior hemin use, and that it reduces

analgesic use and pain both during and between porphyria attacks.
Overall disease burden in the ENVISION trial population was similar to that observed in the recent EXPLORE
study, a prospective, multinational, natural history study

Median Proportion of Days With Opioid Use, %

Wang et al. Orphanet Journal of Rare Diseases

Page 9 of 12

OLE Perioda
(6–24 months)

DB Period
(0–6 months)
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37.8
30.4

30

20
11.1
10

6.3

5.0
1.6

1.5
0

Prior hemin
prophylaxis

No prior hemin
prophylaxis
Placebo crossover

Prior hemin
prophylaxis

1.0

No prior hemin
prophylaxis

Continuous givosiran

Fig. 7 Proportion of days with opioid use in patients with or without prior hemin prophylaxis use. aAnalgesic use was collected in an electronic
diary up to Month 12

DB Period
(0–6 months)

OLE Period
(6–24 months)
9.8

10

Mean Change From Baseline

8.5
7.7

8

7.8

6.4

6

4

3.4
2.7

2
0.3
0

Prior hemin
prophylaxis

No prior hemin
prophylaxis
Placebo crossover

Prior hemin
prophylaxis

No prior hemin
prophylaxis

Continuous givosiran

Fig. 8 Mean change from baseline in SF-12 PCS scores in patients with or without prior hemin prophylaxis use. Higher scores represent
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of patients with AHP experiencing recurrent attacks
[11]. Eligibility criteria for EXPLORE were similar to the
ENVISION trial, with EXPLORE patients needing to
have experienced ≥ 3 attacks in the previous 12 months,

including ≥ 1 attack requiring hemin or treatment at a
hospital or healthcare setting, or be receiving prophylactic treatment to prevent attacks [11]. The median
number of attacks experienced in the 12 months before
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study entry in EXPLORE was 6 [11] compared with 8 in
the ENVISION trial [35]. In EXPLORE, 46% of patients
reported experiencing chronic porphyria symptoms daily
[11] compared with 52% of patients in the ENVISION
trial (symptoms daily or on most days) [35]. QOL at baseline, as assessed by EQ VAS, was diminished to a similar
extent in EXPLORE (66) and ENVISION (about 63–64)
[11]. Of note, rates of psychiatric disorders were higher in
ENVISION than in EXPLORE (depression 27% vs. 18%,
anxiety 23% vs. 8%, insomnia 18% vs. 12%, respectively)
[11].
The proportions of patients with chronic symptoms
in both ENVISION and EXPLORE (52–65%) were considerably higher than those reported in earlier US and
Swedish observational studies (18–22%) [6, 11, 35, 39].
However, the rate of neuropathy in ENVISION (38%) was
similar to that reported in the US observational study
(43%) [6], and rates of kidney disease were also similar
(25% and 29%) [6], suggesting that disease progression
was comparable between studies.
The diagnosis of AHP is frequently delayed for years
due to the non-specific nature of AHP symptoms [6]. In
the US observational study of patients with symptomatic
AHP, the mean time to disease diagnosis was 15 years
[6]. Acute attacks in AHP can be difficult to distinguish
from other common conditions [5, 40]. Delays in AHP
diagnosis are often accompanied by inappropriate treatments for wrongly diagnosed conditions and unnecessary
complications for the patient [41, 42]. Recurrent attacks
of porphyria may lead to progressive or irreversible neuropathy and prolonged debilitation [2, 11].
Despite the high historical AAR, only about 50% of
patients in ENVISION met the European Porphyria
Network (EPNET) classification criteria for recurrent
attacks, which are used as a marker for disease severity
[43]. EPNET defines “recurrent” disease as ≥ 4 attacks in
one or more years requiring hospitalization and hemin
[43]. EPNET disease severity criteria do not include
attacks requiring urgent care or hemin at home and do
not include chronic symptoms of AHP. In comparison,
the inclusion criteria for ENVISION required patients to
have experienced ≥ 2 attacks requiring hospitalization,
urgent care, or IV administration of hemin at home in the
previous 6 months [35]. By using less-strict criteria for
defining recurrent attacks, the ENVISION trial included
patients across a range of disease severity in terms of the
number of acute attacks and setting of acute attack treatment. This enabled an analysis of the long-term burden
of AHP by accounting for multiple measures of disease
severity, including chronic symptoms between attacks,
pain severity and use of opioid analgesics, QOL and lost
days of work, prevalence of comorbidities, prevalence of
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prophylactic hemin use, and complications associated
with hemin prophylaxis [35]. Urgent healthcare visits and
use of hemin at home for acute attacks accounted for 63%
of historical AAR in the ENVISION trial.
Our study also examined disease burden at baseline according to prior hemin use in ENVISION trial
patients and showed that disease burden remained high
in patients who had not received hemin prophylaxis;
approximately 60% experienced chronic symptoms
between attacks, with a median historical AAR of 6 in the
placebo group and 8 in the givosiran group.
In ENVISION, the number of porphyria attacks and
attack severity were both reduced in patients receiving
givosiran compared with those receiving placebo, regardless of prior hemin use. Givosiran recipients had fewer
days with daily worst pain scores above baseline than placebo recipients, and nearly 50% fewer days with severe
pain during attack-free periods. Pain is one of the key
factors associated with diminished QOL among patients
with AHP [11]. The SF-12 PCS scores increased by 10.0
and 8.9 points in the open-label extension in the placebo
crossover and continuous givosiran groups, respectively.
The proportion of patients who used opioid analgesics
during attacks was 12% lower in the givosiran group compared with the placebo group during attacks, and 13%
lower during attack-free periods. Given that long-term
use of opioids is associated with tolerance, dependence,
and addiction, a reduction in use of these medications is
clinically relevant. Furthermore, evidence for the efficacy
of opioids in the management of chronic non–cancerrelated pain is limited. A 30-month open-label extension
phase of ENVISION was completed in May 2021. Results
to date support long-term maintenance of benefit with
givosiran.
A strength of our study is that, unlike the observational
EXPLORE study [11], all potential porphyria attacks
occurring in the ENVISION trial were adjudicated by the
investigator. A limitation of our study was the post hoc
nature of our analyses and lack of prespecified formal
statistical comparisons; therefore, the results should be
interpreted carefully.

Conclusions
In conclusion, the current study highlights the severe disease burden associated with AHP, even in patients with a
relatively low rate of attacks, and supports the effectiveness of givosiran for the management of certain acute
and chronic porphyria symptoms.
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